Document:

EXHIBIT 10.3

         THE SECURITIES  REPRESENTED  HEREBY MAY NOT BE  TRANSFERRED  UNLESS (I)
SUCH  SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF
1933, AS AMENDED,  (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144(K),  OR
(III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY  SATISFACTORY TO
IT THAT SUCH  TRANSFER  MAY  LAWFULLY  BE MADE  WITHOUT  REGISTRATION  UNDER THE
SECURITIES ACT OF 1933 OR QUALIFICATION  UNDER APPLICABLE STATE SECURITIES LAWS.
NOTWITHSTANDING THE FOREGOING,  THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT SECURED BY THE SECURITIES

         SUBJECT TO THE  PROVISIONS OF SECTION 10 HEREOF,  THIS WARRANT SHALL BE
VOID AFTER 5:00 P.M.  EASTERN TIME ON [FIFTH  ANNIVERSARY  OF THE CLOSING  DATE]
(THE "EXPIRATION DATE").

No. __________

                              PHARMAFRONTIERS CORP.

                      WARRANT TO PURCHASE _______ SHARES OF

                     COMMON STOCK, PAR VALUE $0.05 PER SHARE

         For VALUE RECEIVED, ____________________ ("Warrantholder"), is entitled
to purchase,  subject to the  provisions of this Warrant,  from  PharmaFrontiers
Corp., a Texas corporation  ("Company"),  at any time from and after the Initial
Exercise Date (as defined below) and not later than 5:00 P.M.,  Eastern time, on
the Expiration Date (as defined above),  at an exercise price per share equal to
$0.65 (the exercise  price in effect being herein  called the "Warrant  Price"),
______ shares ("Warrant  Shares") of the Company's Common Stock, par value $0.05
per share  ("Common  Stock").  The number of  Warrant  Shares  purchasable  upon
exercise of this  Warrant and the Warrant  Price shall be subject to  adjustment
from time to time as described herein.

         This Warrant is one of a series of Warrants of like tenor issued by the
Company pursuant to that certain Purchase  Agreement dated April 11, 2006, among
the Company and the Investors  named  therein (the  "Purchase  Agreement"),  and
initially  covering an  aggregate  of up to  23,000,0000  shares of Common Stock
(collectively, the "Company Warrants").

         As used herein,  "Initial  Exercise Date" shall mean the effective date
of the  Reverse  Split (as defined in the  Purchase  Agreement).  The  Company's
covenants and agreements relating to the Reverse Split contained in the Purchase
Agreement are hereby  incorporated herein by reference as if set forth herein at
length and the  Warrantholder is hereby made an express third party  beneficiary
thereof with the full right to enforce such  covenants  and  agreements as if it
were a party to the Purchase Agreement.

<PAGE>

         Section 1.  REGISTRATION.  The  Company  shall  maintain  books for the
transfer  and  registration  of the Warrant.  Upon the initial  issuance of this
Warrant,  the Company  shall issue and  register  the Warrant in the name of the
Warrantholder.

         Section  2.  TRANSFERS.   As  provided  herein,  this  Warrant  may  be
transferred only pursuant to a registration statement filed under the Securities
Act of 1933,  as amended  (the  "Securities  Act"),  or an  exemption  from such
registration.  Subject to such  restrictions,  the Company  shall  transfer this
Warrant  from time to time upon the books to be  maintained  by the  Company for
that  purpose,  upon  surrender  hereof  for  transfer,   properly  endorsed  or
accompanied by appropriate instructions for transfer and such other documents as
may be  reasonably  required  by the  Company,  including,  if  required  by the
Company,  an opinion of its counsel to the effect  that such  transfer is exempt
from the registration requirements of the Securities Act, to establish that such
transfer is being made in accordance  with the terms  hereof,  and a new Warrant
shall be issued to the transferee and the surrendered  Warrant shall be canceled
by the Company.

         Section 3. EXERCISE OF WARRANT.  Subject to the provisions  hereof, the
Warrantholder may exercise this Warrant,  in whole or in part, at any time after
the Initial  Exercise  Date and prior to its  expiration  upon  surrender of the
Warrant, together with delivery of a duly executed Warrant exercise form, in the
form attached  hereto as Appendix A (the  "Exercise  Agreement")  and payment by
cash,  certified check or wire transfer of funds (or, in certain  circumstances,
by cashless  exercise as provided below) of the aggregate Warrant Price for that
number of Warrant  Shares then being  purchased,  to the Company  during  normal
business hours on any business day at the Company's  principal executive offices
(or such other office or agency of the Company as it may  designate by notice to
the Warrantholder). The Warrant Shares so purchased shall be deemed to be issued
to the  Warrantholder or the  Warrantholder's  designee,  as the record owner of
such shares, as of the close of business on the date on which this Warrant shall
have  been  surrendered  (or the date  evidence  of loss,  theft or  destruction
thereof and security or indemnity  satisfactory to the Company has been provided
to the  Company),  the  Warrant  Price  shall  have been paid and the  completed
Exercise  Agreement  shall have been  delivered.  Certificates  for the  Warrant
Shares so purchased shall be delivered to the Warrantholder  within a reasonable
time, not exceeding three (3) business days,  after this Warrant shall have been
so exercised.  The  certificates so delivered shall be in such  denominations as
may be requested by the Warrantholder and shall be registered in the name of the
Warrantholder or such other name as shall be designated by the Warrantholder, as
specified in the Exercise  Agreement.  If this Warrant shall have been exercised
only in part, then,  unless this Warrant has expired,  the Company shall, at its
expense,  at  the  time  of  delivery  of  such  certificates,  deliver  to  the
Warrantholder  a new Warrant  representing  the right to purchase  the number of
shares with respect to which this Warrant shall not then have been exercised. As
used herein,  "business  day" means a day,  other than a Saturday or Sunday,  on
which banks in New York City are open for the general  transaction  of business.
Each exercise hereof shall constitute the  re-affirmation  by the  Warrantholder
that the representations  and warranties  contained in Section 5 of the Purchase
Agreement  are true and correct in all  material  respects  with  respect to the
Warrantholder as of the time of such exercise. Notwithstanding the foregoing, to
effect the exercise of the Warrant  hereunder,  the  Warrantholder  shall not be
required to physically  surrender  this Warrant to the Company unless the entire
Warrant is exercised.  The  Warrantholder and the Company shall maintain records
showing the amount exercised and the dates of such exercise.  The  Warrantholder
and any assignee, by acceptance of this Warrant,  acknowledge and agree that, by
reason of the provision of the paragraph, following exercise of a portion of the
Warrant,  the  number of  Warrant  Shares of this  Warrant  may be less than the
amount stated on the face hereof.
<PAGE>
                                      -2-

         Section  4.  COMPLIANCE  WITH THE  SECURITIES  ACT OF 1933.  Except  as
provided in the Purchase  Agreement,  the Company may cause the legend set forth
on the first page of this Warrant to be set forth on each Warrant, and a similar
legend on any security issued or issuable upon exercise of this Warrant,  unless
counsel  for the  Company is of the  opinion as to any such  security  that such
legend is unnecessary.

         Section 5. PAYMENT OF TAXES. The Company will pay any documentary stamp
taxes  attributable to the initial  issuance of Warrant Shares issuable upon the
exercise  of the  Warrant;  provided,  however,  that the  Company  shall not be
required to pay any tax or taxes which may be payable in respect of any transfer
involved in the issuance or delivery of any certificates for Warrant Shares in a
name other than that of the  Warrantholder  in respect of which such  shares are
issued,  and in such case, the Company shall not be required to issue or deliver
any  certificate  for Warrant Shares or any Warrant until the person  requesting
the same has paid to the  Company the amount of such tax or has  established  to
the  Company's  reasonable  satisfaction  that  such  tax  has  been  paid.  The
Warrantholder shall be responsible for income taxes due under federal,  state or
other law, if any such tax is due.

         Section 6. MUTILATED OR MISSING WARRANTS. In case this Warrant shall be
mutilated,  lost, stolen, or destroyed,  the Company shall issue in exchange and
substitution of and upon surrender and cancellation of the mutilated Warrant, or
in lieu of and  substitution  for the Warrant lost,  stolen or destroyed,  a new
Warrant of like tenor and for the  purchase of a like number of Warrant  Shares,
but only upon receipt of evidence reasonably satisfactory to the Company of such
loss, theft or destruction of the Warrant, and with respect to a lost, stolen or
destroyed  Warrant,  reasonable  indemnity  or bond  with  respect  thereto,  if
requested by the Company.

         Section 7.  RESERVATION OF COMMON STOCK.  At any time when this Warrant
is  exercisable,  the Company shall at all applicable  times keep reserved until
issued (if necessary) as  contemplated  by this Section 7, out of the authorized
and  unissued  shares of Common  Stock,  sufficient  shares to  provide  for the
exercise  of the rights of purchase  represented  by this  Warrant.  The Company
agrees that all Warrant Shares issued upon due exercise of the Warrant shall be,
at the time of  delivery  of the  certificates  for such  Warrant  Shares,  duly
authorized, validly issued, fully paid and non-assessable shares of Common Stock
of the Company.

         Section 8. ADJUSTMENTS.  Subject and pursuant to the provisions of this
Section  8, the  Warrant  Price and  number of  Warrant  Shares  subject to this
Warrant  shall  be  subject  to  adjustment  from  time  to  time  as set  forth
hereinafter.

                  (a) If the  Company  shall,  at any time or from  time to time
while this Warrant is outstanding,  pay a dividend or make a distribution on its
Common Stock in shares of Common  Stock,  subdivide  its  outstanding  shares of
Common Stock into a greater number of shares or combine its  outstanding  shares
of Common Stock into a smaller number of shares or issue by  reclassification of
its  outstanding  shares  of  Common  Stock  any  shares  of its  capital  stock
(including  any such  reclassification  in connection  with a  consolidation  or
merger in which the Company is the continuing corporation), then (i) the Warrant
Price in effect  immediately prior to the date on which such change shall become
effective shall be adjusted by multiplying such Warrant Price by a fraction, the
numerator  of which  shall be the number of shares of Common  Stock  outstanding
immediately  prior to such  change  and the  denominator  of which  shall be the
number of shares of Common Stock outstanding  immediately after giving effect to
such change and (ii) the number of Warrant Shares  purchasable  upon exercise of
this  Warrant  shall be adjusted  by  multiplying  the number of Warrant  Shares
purchasable upon exercise of this Warrant immediately prior to the date on which
such change shall  become  effective  by a fraction,  the  numerator of which is
shall be the Warrant Price in effect immediately prior to the date on which such
change shall become  effective and the denominator of which shall be the Warrant
Price in effect  immediately  after giving effect to such change,  calculated in
accordance with clause (i) above.  Such adjustments  shall be made  successively
whenever any event listed above shall occur.

                                      -3-
<PAGE>

                  (b) If any  capital  reorganization,  reclassification  of the
capital  stock of the  Company,  consolidation  or  merger of the  Company  with
another corporation in which the Company is not the survivor,  or sale, transfer
or other  disposition  of all or  substantially  all of the Company's  assets to
another   corporation   shall  be  effected,   then,  as  a  condition  of  such
reorganization, reclassification, consolidation, merger, sale, transfer or other
disposition,   lawful  and  adequate   provision  shall  be  made  whereby  each
Warrantholder  shall  thereafter have the right to purchase and receive upon the
basis and upon the  terms and  conditions  herein  specified  and in lieu of the
Warrant Shares  immediately  theretofore  issuable upon exercise of the Warrant,
such  shares of stock,  securities  or assets  as would  have been  issuable  or
payable with  respect to or in exchange for a number of Warrant  Shares equal to
the number of Warrant Shares immediately  theretofore  issuable upon exercise of
the Warrant, had such reorganization,  reclassification,  consolidation, merger,
sale,  transfer  or other  disposition  not  taken  place,  and in any such case
appropriate  provision shall be made with respect to the rights and interests of
each  Warrantholder to the end that the provisions  hereof  (including,  without
limitation,  provision for adjustment of the Warrant Price) shall  thereafter be
applicable, as nearly equivalent as may be practicable in relation to any shares
of stock,  securities or assets thereafter deliverable upon the exercise hereof.
The Company shall not effect any such consolidation,  merger,  sale, transfer or
other  disposition  unless  prior to or  simultaneously  with  the  consummation
thereof the successor  corporation  (if other than the Company)  resulting  from
such  consolidation  or  merger,  or the  corporation  purchasing  or  otherwise
acquiring  such assets or other  appropriate  corporation or entity shall assume
the  obligation  to deliver  to the  Warrantholder,  at the last  address of the
Warrantholder  appearing  on the  books of the  Company,  such  shares of stock,
securities  or assets  as, in  accordance  with the  foregoing  provisions,  the
Warrantholder may be entitled to purchase,  and the other obligations under this
Warrant.  The  provisions  of  this  paragraph  (b)  shall  similarly  apply  to
successive reorganizations,  reclassifications,  consolidations, mergers, sales,
transfers or other dispositions.

                  (c) In case  the  Company  shall  fix a  payment  date for the
making of a  distribution  to all holders of Common  Stock  (including  any such
distribution  made in  connection  with a  consolidation  or merger in which the
Company is the continuing  corporation)  of evidences of  indebtedness or assets
(other than cash  dividends or cash  distributions  payable out of  consolidated
earnings or earned surplus or dividends or distributions  referred to in Section
8(a)),  or  subscription  rights or warrants,  the Warrant Price to be in effect
after such payment date shall be determined by multiplying  the Warrant Price in
effect  immediately  prior to such payment date by a fraction,  the numerator of
which shall be the total number of shares of Common Stock outstanding multiplied
by the Market  Price (as defined  below) per share of Common  Stock  immediately
prior to such payment  date,  less the fair market value (as  determined  by the
Company's  Board of  Directors  in good  faith) of said assets or  evidences  of
indebtedness so distributed, or of such subscription rights or warrants, and the
denominator  of which  shall be the total  number  of  shares  of  Common  Stock
outstanding   multiplied  by  such  Market  Price  per  share  of  Common  Stock
immediately  prior to such payment date.  "Market Price" as of a particular date
(the "Valuation Date") shall mean the following: (a) if the Common Stock is then
listed on a national  stock  exchange,  the  closing  sale price of one share of
Common  Stock on such  exchange on the last  trading day prior to the  Valuation
Date;  (b) if the Common Stock is then quoted on The Nasdaq Stock  Market,  Inc.
("Nasdaq"),  the National  Association of Securities Dealers,  Inc. OTC Bulletin
Board (the "Bulletin  Board") or such similar  quotation  system or association,
the  closing  sale price of one share of Common  Stock on Nasdaq,  the  Bulletin
Board or such other  quotation  system or  association  on the last  trading day
prior to the Valuation Date or, if no such closing sale price is available,  the
average  of the high bid and the low  asked  price  quoted  thereon  on the last
trading day prior to the Valuation  Date; or (c) if the Common Stock is not then
listed on a national stock  exchange or quoted on Nasdaq,  the Bulletin Board or
such other quotation  system or association,  the fair market value of one share
of Common Stock as of the  Valuation  Date,  as  determined in good faith by the
Board of Directors of the Company and the Warrantholder.  If the Common Stock is
not then listed on a national securities exchange, Nasdaq, the Bulletin Board or
such  other  quotation  system or  association,  the Board of  Directors  of the
Company shall respond promptly,  in writing,  to an inquiry by the Warrantholder
prior to the exercise hereunder as to the fair market value of a share of Common
Stock as determined by the Board of Directors of the Company.  In the event that
the Board of Directors of the Company and the  Warrantholder are unable to agree
upon the fair  market  value in respect of subpart  (c) of this  paragraph,  the
Company  and  the  Warrantholder  shall  jointly  select  an  appraiser,  who is
experienced in such matters.  The decision of such appraiser  shall be final and
conclusive, and the cost of such appraiser shall be borne equally by the Company
and the Warrantholder.  Such adjustment shall be made successively whenever such
a payment date is fixed.

                                      -4-
<PAGE>

                  (d) An adjustment to the Warrant Price shall become  effective
immediately  after the payment date in the case of each dividend or distribution
and  immediately  after the effective date of each other event which requires an
adjustment.

                  (e) In the  event  that,  as a result  of an  adjustment  made
pursuant to this Section 8, the  Warrantholder  shall become entitled to receive
any shares of capital  stock of the Company  other than shares of Common  Stock,
the number of such other  shares so  receivable  upon  exercise of this  Warrant
shall be subject  thereafter to adjustment  from time to time in a manner and on
terms as nearly  equivalent as practicable to the provisions with respect to the
Warrant Shares contained in this Warrant.

                  (f) To the extent  permitted by applicable law and the listing
requirements  of any stock  market or exchange on which the Common Stock is then
listed,  the Company  from time to time may  decrease  the Warrant  Price by any
amount for any period of time if the period is at least  twenty  (20) days,  the
decrease  is  irrevocable  during  the  period  and the Board  shall have made a
determination  that such decrease would be in the best interests of the Company,
which determination shall be conclusive. Whenever the Warrant Price is decreased
pursuant to the preceding  sentence,  the Company shall provide  written  notice
thereof  to the  Warrantholder  at least  five  (5)  days  prior to the date the
decreased Warrant Price takes effect,  and such notice shall state the decreased
Warrant Price and the period during which it will be in effect.  Notwithstanding
the  foregoing,  the Company  shall  treat all  holders of the Company  Warrants
equally.

                                      -5-
<PAGE>

         Section 9.  FRACTIONAL  INTEREST.  The Company shall not be required to
issue  fractions  of Warrant  Shares upon the exercise of this  Warrant.  If any
fractional  share of Common Stock would,  except for the provisions of the first
sentence of this Section 9, be deliverable upon such exercise,  the Company,  in
lieu  of  delivering  such  fractional  share,   shall  pay  to  the  exercising
Warrantholder  an amount in cash  equal to the Market  Price of such  fractional
share of Common Stock on the date of exercise.

         Section 10. EXTENSION OF EXPIRATION DATE. If the Company fails to cause
any Registration  Statement  covering  Registrable  Securities (unless otherwise
defined  herein,  capitalized  terms are as defined in the  Registration  Rights
Agreement relating to the Warrant Shares (the "Registration  Rights Agreement"))
to be declared effective prior to the applicable dates set forth therein,  or if
any of the events  specified  in Section  2(c)(ii)  of the  Registration  Rights
Agreement occurs, and the Blackout Period (whether alone, or in combination with
any  other  Blackout  Period)  continues  for more  than 60 days in any 12 month
period,  or for more than a total of 90 days,  then the Expiration  Date of this
Warrant  shall be  extended  one day for each day  beyond  the  60-day or 90-day
limits, as the case may be, that the Blackout Period continues.

         Section 11.  BENEFITS.  Nothing in this  Warrant  shall be construed to
give  any  person,   firm  or  corporation  (other  than  the  Company  and  the
Warrantholder)  any legal or equitable  right,  remedy or claim, it being agreed
that this Warrant shall be for the sole and exclusive benefit of the Company and
the Warrantholder.

         Section 12. NOTICES TO  WARRANTHOLDER.  Upon the happening of any event
requiring an adjustment of the Warrant  Price,  the Company shall  promptly give
written  notice  thereof to the  Warrantholder  at the address  appearing in the
records of the  Company,  stating the  adjusted  Warrant  Price and the adjusted
number of  Warrant  Shares  resulting  from  such  event  and  setting  forth in
reasonable  detail  the  method of  calculation  and the facts  upon  which such
calculation is based.  Failure to give such notice to the  Warrantholder  or any
defect  therein  shall not  affect  the  legality  or  validity  of the  subject
adjustment.

         Section 13.  IDENTITY OF TRANSFER  AGENT.  The  Transfer  Agent for the
Common Stock is Continental  Stock Transfer & Trust. Upon the appointment of any
subsequent  transfer agent for the Common Stock or other shares of the Company's
capital stock  issuable upon the exercise of the rights of purchase  represented
by the Warrant,  the Company will mail to the  Warrantholder a statement setting
forth the name and address of such transfer agent.

         Section 14. NOTICES.  Unless otherwise provided, any notice required or
permitted  under  this  Warrant  shall be given in  writing  and shall be deemed
effectively given and received as hereinafter described (i) if given by personal
delivery,  then such notice shall be deemed received upon such delivery, (ii) if
given by telex or  facsimile,  then such notice  shall be deemed  received  upon
receipt of  confirmation  of complete  transmittal,  (iii) if given by certified
mail return receipt  requested,  then such notice shall be deemed  received upon
the day such return receipt is signed,  and (iv) if given by an  internationally
recognized  overnight  air  courier,  then such notice shall be deemed given one
business day after  delivery to such carrier.  Copies of such notices shall also
be transmitted by email to the email address  provided for on the signature page
of the Purchase Agreement.  All notices shall be addressed as follows: if to the
Warrantholder,  at its address as set forth in the  Company's  books and records
and, if to the Company,  at the address as follows,  or at such other address as
the  Warrantholder  or the Company may  designate by ten days'  advance  written
notice to the other:

                                      -6-
<PAGE>

                           If to the Company:

                                    PharmaFrontiers Corp.
                                    2635 Crescent Ridge Drive
                                    The Woodlands, Texas 77381
                                    Attention:  William Rouse
                                    Fax:  (281) 872-8585

                           With a copy to:

                                    Brewer & Pritchard, P.C.
                                    Three Riverway, 18th Floor
                                    Houston, Texas 77056
                                    Attention:  Thomas Pritchard, Esq.
                                    Fax:  (713) 659-5302

         Section 15. REGISTRATION RIGHTS. The initial  Warrantholder is entitled
to the  benefit of certain  registration  rights  with  respect to the shares of
Common  Stock  issuable  upon the  exercise  of this  Warrant as provided in the
Registration Rights Agreement,  and any subsequent Warrantholder may be entitled
to such rights.

         Section 16.  SUCCESSORS.  All the covenants and provisions hereof by or
for the benefit of the Warrantholder  shall bind and inure to the benefit of its
respective successors and assigns hereunder.

         Section 17.  GOVERNING  LAW;  CONSENT TO  JURISDICTION;  WAIVER OF JURY
TRIAL.  This Warrant shall be governed by, and construed in accordance with, the
internal laws of the State of New York,  without  reference to the choice of law
provisions   thereof.   The  Company  and,  by  accepting   this  Warrant,   the
Warrantholder,  each  irrevocably  submits to the exclusive  jurisdiction of the
courts of the State of New York located in New York County and the United States
District  Court for the  Southern  District  of New York for the  purpose of any
suit, action,  proceeding or judgment relating to or arising out of this Warrant
and the transactions  contemplated hereby. Service of process in connection with
any such suit,  action or proceeding may be served on each party hereto anywhere
in the world by the same  methods  as are  specified  for the  giving of notices
under  this  Warrant.   The  Company  and,  by  accepting   this  Warrant,   the
Warrantholder,  each irrevocably  consents to the jurisdiction of any such court
in any such suit, action or proceeding and to the laying of venue in such court.
The Company and, by accepting this Warrant, the Warrantholder,  each irrevocably
waives  any  objection  to the  laying  of  venue of any such  suit,  action  or
proceeding brought in such courts and irrevocably waives any claim that any such
suit,  action or  proceeding  brought in any such  court has been  brought in an
inconvenient  forum.  EACH OF THE COMPANY  AND, BY ITS  ACCEPTANCE  HEREOF,  THE
WARRANTHOLDER  HEREBY  WAIVES  ANY  RIGHT  TO  REQUEST  A  TRIAL  BY JURY IN ANY
LITIGATION  WITH  RESPECT TO THIS WARRANT AND  REPRESENTS  THAT COUNSEL HAS BEEN
CONSULTED SPECIFICALLY AS TO THIS WAIVER.

                                      -7-
<PAGE>

         Section  18.  CALL  PROVISION.   Notwithstanding  any  other  provision
contained in this Warrant to the contrary, in the event that (i) the closing bid
price per share of Common Stock as traded on the  Bulletin  Board (or such other
exchange or stock market on which the Common Stock may then be listed or quoted)
equals or exceeds  $1.30  (appropriately  adjusted for any stock split,  reverse
stock split,  stock  dividend or other  reclassification  or  combination of the
Common  Stock  occurring  after the date  hereof)  for twenty  (20)  consecutive
trading days commencing after the first anniversary of the date the Registration
Statement (as defined in the  Registration  Rights  Agreement) has been declared
effective  and (ii) during such period of twenty (20)  consecutive  trading days
the daily average  trading volume of the common Stock is at least 200,000 shares
(appropriately adjusted for any stock split, reverse stock split, stock dividend
or other reclassification or combination of the Common Stock occurring after the
date  hereof),  the  Company,  upon thirty (30) days prior  written  notice (the
"Notice  Period")  given  to  the  Warrantholder   within  three  business  days
immediately  following  the end of any such twenty (20) trading day period,  may
demand that the Warrantholder  exercise its cash exercise rights hereunder,  and
the Warrantholder  must exercise its rights  hereunder,  up to any limitation on
the amount to be exercised  provided for in Section 23 hereof,  prior to the end
of the Notice  Period;  provided  that (i) the  Company  simultaneously  gives a
similar notice to all holders of Company  Warrants and (ii) all of the shares of
Common  Stock  issuable  hereunder  either  (A) are  registered  pursuant  to an
effective   Registration  Statement  (as  defined  in  the  Registration  Rights
Agreement)  which  has not been  suspended  and for  which  no stop  order is in
effect,  and pursuant to which the  Warrantholder is able to sell such shares of
Common Stock at all times during the Notice  Period or (B) no longer  constitute
Registrable Securities (as defined in the Registration Rights Agreement). Except
for any limitation on the amount to be exercised  pursuant to Section 23 hereof,
if such exercise is not made or if only a partial  exercise is made, any and all
rights to further  exercise the Warrant  shall cease upon the  expiration of the
Notice Period and this Warrant or such  unexercised  portion hereof shall become
null and void.

                                      -8-
<PAGE>

         Section 19.  CASHLESS  EXERCISE.  Notwithstanding  any other  provision
contained  herein to the contrary,  from and after the first  anniversary of the
Closing Date (as defined in the Purchase  Agreement)  and so long as the Company
is  required  under the  Registration  Rights  Agreement  to have  effected  the
registration  of the  Warrant  Shares  for resale to the  public  pursuant  to a
Registration  Statement  (as such term is  defined  in the  Registration  Rights
Agreement),  if the  Warrant  Shares  may not be freely  sold to the public as a
result of a breach by the  Company  of its  obligations  under the  Registration
Rights Agreement, the Warrantholder may elect to receive, without the payment by
the  Warrantholder  of the  aggregate  Warrant Price in respect of the shares of
Common Stock to be acquired,  shares of Common Stock of equal value to the value
of this  Warrant,  or any  specified  portion  hereof,  by the surrender of this
Warrant (or such portion of this Warrant being so exercised) together with a Net
Issue Election Notice,  in the form annexed hereto as Appendix B, duly executed,
to the Company.  Thereupon,  the Company shall issue to the  Warrantholder  such
number of fully paid, validly issued and nonassessable shares of Common Stock as
is computed using the following formula:

                                  X = Y (A - B)
                                      ---------
                                          A

where

                   X = the  number  of  shares  of  Common  Stock to  which  the
Warrantholder is entitled upon such cashless exercise;

                   Y = the total  number of shares of Common  Stock  covered  by
this Warrant for which the Warrantholder has surrendered purchase rights at such
time  for  cashless  exercise  (including  both  shares  to  be  issued  to  the
Warrantholder  and shares as to which the purchase  rights are to be canceled as
payment therefor);

                   A = the "Market Price" of one share of Common Stock as of the
date the net issue election is made; and

                   B = the  Warrant  Price in effect  under this  Warrant at the
time the net issue election is made.

         Section 20.       NO RIGHTS AS  STOCKHOLDER.  Prior to the  exercise of
this  Warrant,  the  Warrantholder  shall not have or  exercise  any rights as a
stockholder of the Company by virtue of its ownership of this Warrant.

         Section 21. AMENDMENT;  WAIVER. Any term of this Warrant may be amended
or waived  (including  the adjustment  provisions  included in Section 8 of this
Warrant)  upon the  written  consent of the  Company  and the holders of Company
Warrants  representing at least 50% of the number of shares of Common Stock then
subject to all outstanding Company Warrants (the "Majority Holders");  PROVIDED,
that (x) any such  amendment or waiver must apply to all Company  Warrants;  and
(y) the number of Warrant Shares subject to this Warrant,  the Warrant Price and
the Expiration  Date may not be amended,  and the right to exercise this Warrant
may not be altered or waived, without the written consent of the Warrantholder.

         Section 22. SECTION HEADINGS.  The section headings in this Warrant are
for the  convenience of the Company and the  Warrantholder  and in no way alter,
modify, amend, limit or restrict the provisions hereof.

         [Section 23A. LIMITATIONS ON EXERCISE.  Notwithstanding anything to the
contrary  contained herein, the number of Warrant Shares that may be acquired by
the  Warrantholder  upon any exercise of this  Warrant (or  otherwise in respect
hereof) shall be limited to the extent necessary to insure that,  following such
exercise  (or other  issuance),  the total number of shares of Common Stock then
beneficially  owned  by such  Warrantholder  and its  Affiliates  and any  other
Persons whose beneficial  ownership of Common Stock would be aggregated with the
Warrantholder's  for  purposes of Section  13(d) of the Exchange  Act,  does not
exceed  9.999% of the total  number of issued and  outstanding  shares of Common
Stock  (including for such purpose the shares of Common Stock issuable upon such
exercise of the Company Warrants). For such purposes, beneficial ownership shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules
and regulations  promulgated  thereunder.  This provision shall not restrict the
number  of  shares  of  Common  Stock  which  a  Warrantholder  may  receive  or
beneficially  own in  order to  determine  the  amount  of  securities  or other
consideration  that such Warrantholder may receive in the event of a transaction
contemplated by Section 8 of this Warrant. This restriction may not be waived.

                                      -9-
<PAGE>

         Section 23B. LIMITATIONS ON EXERCISE.  Notwithstanding  anything to the
contrary  contained herein, the number of Warrant Shares that may be acquired by
the  Warrantholder  upon any exercise of this  Warrant (or  otherwise in respect
hereof) shall be limited to the extent necessary to insure that,  following such
exercise  (or other  issuance),  the total number of shares of Common Stock then
beneficially  owned  by such  Warrantholder  and its  Affiliates  and any  other
Persons whose beneficial  ownership of Common Stock would be aggregated with the
Warrantholder's  for  purposes of Section  13(d) of the Exchange  Act,  does not
exceed  19.999% of the total number of issued and  outstanding  shares of Common
Stock  (including for such purpose the shares of Common Stock issuable upon such
exercise of the Company Warrants). For such purposes, beneficial ownership shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules
and regulations  promulgated  thereunder.  This provision shall not restrict the
number  of  shares  of  Common  Stock  which  a  Warrantholder  may  receive  or
beneficially  own in  order to  determine  the  amount  of  securities  or other
consideration  that such Warrantholder may receive in the event of a transaction
contemplated  by  Section  8 of  this  Warrant.  This  restriction  may  not  be
waived](1)

--------------------------
(1) To be included only at the specific  request of an Investor on the Signature
    Page of the Purchase Agreement.

                                      -10-
<PAGE>

                   IN WITNESS WHEREOF, the Company has caused this Warrant to be
duly executed, as of the ______ day of ___________, 2006.

                              PHARMAFRONTIERS CORP.

                              By:___________________________
                              Name:
                              Title:

                                      -11-EXHIBIT 10.4

                              SECOND AMENDMENT TO
                     AMENDED AND RESTATED LICENSE AGREEMENT

         This  Second  Amendment  to  Amended  and  Restated  License  Agreement
("Second  Amendment")  effective this _______ day of April,  2006 is between the
University of Chicago, an Illinois  not-for-profit  corporation  ("UNIVERSITY"),
having its principal  office at 5555 S. Woodlawn Avenue,  Chicago,  IL 60637 and
PharmaFrontiers  Corp.,  a Texas  corporation  ("PHARMA")  having its  principal
office at 2635 N.  Crescent  Ridge  Drive,  The  Woodlands,  Texas  77381.  Each
hereunder  may be referred to separately  as the  ("Party"),  or together as the
("Parties"). The Parties agree:

                                                     RECITALS

A.            UNIVERSITY and PHARMA have  previously  entered in an "Amended and
              Restated License  Agreement" dated December 30, 2004 (the "License
              Agreement"); and

B.            UNIVERSITY  and  PHARMA  have  previously   entered  in  a  "First
              Amendment to Amended and Restated License Agreement" dated October
              31, 2005 (the First Amendment); and

C.            NOW,  THEREFORE,  in  consideration  of the  mutual  promises  and
              obligations  hereinafter set forth and for other good and valuable
              consideration,  the  receipt and  sufficiency  of which are hereby
              acknowledged, the Parties hereto agree as follows:

                  1.0      AMENDMENT   OF   PARAGRAPH   4.C.I  OF  THE   LICENSE
                           AGREEMENT,  AS AMENDED IN SECTION B. 1.0 OF THE FIRST
                           AMENDMENT:  The first  sentence  of  Paragraph  4.C.i
                           shall be deleted and replaced with

                               "PF shall pay to the  University one and one half
                               million ($1,500,000) US dollars upon the later of
                               the occurrence of the First  Financing or October
                               31, 2006."

                      Also,  in each instance in which the date "April 30, 2006"
                      appears in  Paragraph  4.C.i.  such date shall be replaced
                      with "October 31, 2006".

                  2.0      AMENDMENT   OF   PARAGRAPH   4.C.II  OF  THE  LICENSE
                           AGREEMENT:   In  each  instance  in  which  the  date
                           "November 30, 2005" appears in Paragraph 4.C.ii, such
                           date will be replaced with October 31, 2006.

                  3.0      No Other  Amendments.  This Second Amendment shall be
                           construed as part of the License Agreement. Except as
                           specifically  amended herein,  the License  Agreement
                           shall remain in full force and effect.

<PAGE>

         IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
executed by their  respective duly authorized  officers or  representatives  and
signed below.

UNIVERSITY OF CHICAGO                        PHARMAFRONTIERS CORP.

By: Alan Thomas                              By:  David B. McWilliams
--------------------------------------       ----------------------------------
Name:  Alan Thomas                           Name:  David B. McWilliams
Title: Director of Technology Transfer       Title:  Chief Executive Officer
Date:  April ________, 2006                  Date:    April ________, 2006

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]